Fujian Genohope Biotech Ltd.

Fujian Genohope Biotech Ltd., is founded by New Hope Group, a Fortune Global 500 company, together with Genovior, fomous Taiwan peptide company and now a member of the Polaris Pharma Group, as the globalized center for R&D and production of peptide products, located in the National Biotech and Health Industry Zone of Across-Strait in Putian City, Fujian Province.

The company focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with a capacity of tons.

In 2023, Genehope has been rewarded as Specialized and Novel Enterprise of Fujian Province.
In 2023 June, the US FDA completed its first on-site inspection for Genohope.